51 - References

References

Drug treatment of psychiatric symptoms in the context of other conditions CHAPTER 10 References

1. Chen LY, et al. Epidemiology of atrial fibrillation: a current perspective. Heart Rhythm 2007; 4:S1–S6.
2. Tully PJ, et al. Anxiety, depression, and stress as risk factors for atrial fibrillation after cardiac surgery. Heart Lung 2011; 40:4–11.
3. National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management. NICE guideline [NG196]. 2021 (last accessed August 2024); https://www.nice.org.uk/guidance/ng196.
4. Lakshminarayan K, et al. Clinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States. Neurologist 2008; 14:143–150.
5. Rodgers M, et al. Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation. Health Technol Assess 2008; 12:iii–iv, xi–xiii, 1–198.
6. Latchamsetty R, et al. Catheter ablation of atrial fibrillation. Cardiol Clin 2014; 32:551–561.
7. Saglietto A, et al. Impact of atrial fibrillation catheter ablation on mortality, stroke, and heart failure hospitalizations: a meta-­analysis. J Cardiovasc Electrophysiol 2020; 31:1040–1047.
8. Hagengaard L, et  al. Incident atrial fibrillation and risk of psychoactive drug redemptions and psychiatric hospital contacts: a Danish Nationwide Register-­based Follow-­up Study. Eur Heart J Qual Care Clin Outcomes 2021; 7:76–82.
9. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327:227–233.
10. Epstein AE, et al. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA 1993; 270:2451–2455.
11. Zhang N, et  al. Prolonged corrected QT interval in predicting atrial fibrillation: a systematic review and meta-­analysis. Pacing Clin Electrophysiol 2018; 41:321–327.
12. Emul M, et al. P wave and QT changes among inpatients with schizophrenia after parenteral ziprasidone administration. Pharmacol Res 2009; 60:369–372.
13. Chou RH, et al. Antipsychotic treatment is associated with risk of atrial fibrillation: a nationwide nested case-­control study. Int J Cardiol 2017; 227:134–140.
14. Chen CM, et al. Major bleeding risk in atrial fibrillation patients co-­medicated with non-­vitamin K oral anticoagulants and antipsychotics. Front Pharmacol 2022; 13:819878.
15. Cam B, et al. [Clozapine and olanzapine associated atrial fibrillation: a case report]. Turk Psikiyatri Dergisi 2015; 26:221–226.
16. Low Jr, RA, et al. Clozapine induced atrial fibrillation. J Clin Psychopharmacol 1998; 18:170.
17. Waters BM, et al. Olanzapine-­associated new-­onset atrial fibrillation. J Clin Psychopharmacol 2008; 28:354–355.
18. Yaylaci S, et al. Atrial fibrillation due to olanzapine overdose. Clin Toxicol (Phila) 2011; 49:440. Condition Suggested drugs Drugs to avoid Anxiety disorders (anxiety symptoms increase risk of AF)45 Benzodiazepines (although a 2022 cohort study found a hugely increased risk of incident AF in benzodiazepine users46) SSRIs (see above) Tricyclics (see above) Several reported cases of pregabalin-­ and gabapentin-­associated AF47,48 and one cohort study suggested increased risk of AF49 with both drugs Promethazine may increase the risk of being hospitalised with AF50 Alzheimer’s disease Acetylcholinesterase inhibitors (but beware bradycardic effects in patients with paroxysmal ’vagal’ AF [paroxysmal AF provoked by low heart rate]) Rivastigmine has least interaction potential Memantine may be able to prevent and terminate AF51 Avoid cholinesterase inhibitors in paroxysmal ‘vagal’ AF AV, atrioventricular; DOACs, direct-­acting oral anticoagulants. Table 10.15  (Continued)

848 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 10 19. D’Urso G, et  al. Aripiprazole-­induced atrial fibrillation in a patient with concomitant risk factors. Exp Clin Psychopharmacol 2018; 26:509–513. 20. Stefatos A, et al. Atrial fibrillation and injected aripiprazole: a case report. Innov Clin Neurosci 2018; 15:43–45. 21. Schneider RA, et al. Apparent seizure and atrial fibrillation associated with paliperidone. Am J Health Syst Pharm 2008; 65:2122–2125. 22. Zeng J, et al. Metabolic disorder caused by antipsychotic treatment may facilitate the development of atrial fibrillation. Int J Cardiol 2017; 239:14. 23. Polcwiartek C, et al. Electrocardiogram characteristics and their association with psychotropic drugs among patients with schizophrenia. Schizophr Bull 2020; 46:354–362. 24. Davutoglu V, et al. Valproic acid as a cause of transient atrio-­ventricular conduction block episodes. J Atr Fibrillation 2017; 9:1520. 25. Kalcik MDM, et al. Acute atrial fibrillation as an unusual form of cardiotoxicity in chronic lithium overdose. J Atr Fibrillation 2014; 6:1009. 26. Acharya S, et al. Lithium-­induced cardiotoxicity: a rare clinical entity. Cureus 2020; 12:e7286. 27. Lange HW, et al. Depressive symptoms predict recurrence of atrial fibrillation after cardioversion. J Psychosom Res 2007; 63:509–513. 28. Patel D, et al. A systematic review of depression and anxiety in patients with atrial fibrillation: the mind-­heart link. Cardiovasc Psychiatry Neurol 2013; 2013:159850. 29. Quinn GR, et al. Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. Am J Cardiol 2014; 114:583–586. 30. Komen JJ, et al. Concomitant anticoagulant and antidepressant therapy in atrial fibrillation patients and risk of stroke and bleeding. Clin Pharmacol Ther 2020; 107:287–294. 31. Pousti A, et al. Effect of sertraline on ouabain-­induced arrhythmia in isolated guinea-­pig atria. Depress Anxiety 2009; 26:E106–E110. 32. Pousti A, et al. Effect of citalopram on ouabain-­induced arrhythmia in isolated guinea-­pig atria. Hum Psychopharmacol 2003; 18:121–124. 33. Shirayama T, et al. Usefulness of paroxetine in depressed men with paroxysmal atrial fibrillation. Am J Cardiol 2006; 97:1749–1751. 34. Emul M, et  al. The influences of depression and venlafaxine use at therapeutic doses on atrial conduction. J Psychopharmacol 2009; 23:163–167. 35. Finch SJ, et al. Cardioversion of persistent atrial arrhythmia after treatment with venlafaxine in successful management of major depression and posttraumatic stress disorder. Psychosomatics 2006; 47:533–536. 36. Shao IY, et al. Association of type of antidepressant initiation with bleeding risk in atrial fibrillation patients taking oral anticoagulants. Drugs Real World Outcomes 2021; 8:383–391. 37. Chang KH, et al. Major bleeding risk in patients with non-­valvular atrial fibrillation concurrently taking direct oral anticoagulants and antidepressants. Front Aging Neurosci 2022; 14:791285. 38. Andrade C. Antidepressants and atrial fibrillation: the importance of resourceful statistical approaches to address confounding by indication. J Clin Psychiatry 2019; 80:19f12729. 39. Fenger-­Grøn M, et al. Depression, antidepressants, and the risk of non-­valvular atrial fibrillation: a nationwide Danish matched cohort study. Eur J Prevent Cardiol 2019; 26:187–195. 40. Taylor D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. Acta Psychiatr Scand 2008; 118:434–442. 41. Moorehead CN, et al. Imipramine-­induced auricular fibrillation. Am J Psychiatry 1965; 122:216–217. 42. Rosen BH. Case report of auricular fibrillation following the use of imipramine (Tofranil). J Mt Sinai Hosp NY 1960; 27:609–611. 43. Lapi F, et al. The use of antidepressants and the risk of chronic atrial fibrillation. J Clin Pharmacol 2015; 55:423–430. 44. Fu Y, et al. Association of depression, antidepressants with atrial fibrillation risk: a systemic review and meta-­analysis. Front Cardiovasc Med 2022; 9:897622. 45. Eaker ED, et al. Tension and anxiety and the prediction of the 10-­year incidence of coronary heart disease, atrial fibrillation, and total mortality: the Framingham Offspring Study. Psychosom Med 2005; 67:692–696. 46. Hu X, et al. Hypnotics use is associated with elevated incident atrial fibrillation: a propensity-­score matched analysis of cohort study. J Pers Med 2022; 12:1645. 47. Chilkoti G, et al. Could pregabalin premedication predispose to perioperative atrial fibrillation in patients with sepsis? Saudi J Anaesth 2014; 8 Suppl 1:S115–S116. 48. Park SH, et al. Atrial fibrillation induced by gabapentin: a case report. J Med Case Rep 2023; 17:236. 49. Ortiz de Landaluce L, et al. Gabapentin and pregabalin and risk of atrial fibrillation in the elderly: a population-­based cohort study in an electronic prescription database. Drug Saf 2018; 41:1325–1331. 50. Sessa M, et al. The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine. Expert Opin Drug Saf 2020; 19:349–357. 51. Xie D, et al. Memantine targets glutamate receptors in atrial cardiomyocytes to prevent and treat atrial fibrillation. Cell Discov 2022; 8:76.